| 000 | 01691 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513123323.0 | ||
| 264 | 0 | _c19971021 | |
| 008 | 199710s 0 0 eng d | ||
| 022 | _a0305-1870 | ||
| 024 | 7 |
_a10.1111/j.1440-1681.1997.tb01233.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSmith, A D | |
| 245 | 0 | 0 |
_aCompetition of adenine nucleotides for a 1,3-[3H]-dipropyl-8-cyclopentylxanthine binding site in rat vas deferens. _h[electronic resource] |
| 260 |
_bClinical and experimental pharmacology & physiology _cJul 1997 |
||
| 300 |
_a492-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a2-Chloroadenosine _xmetabolism |
| 650 | 0 | 4 |
_aAdenine Nucleotides _xmetabolism |
| 650 | 0 | 4 |
_aAdenosine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAdenosine Triphosphate _xmetabolism |
| 650 | 0 | 4 | _aAdenosine-5'-(N-ethylcarboxamide) |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBinding Sites |
| 650 | 0 | 4 |
_aBinding, Competitive _xdrug effects |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aKinetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPurinergic P1 Receptor Agonists |
| 650 | 0 | 4 | _aPurinergic P1 Receptor Antagonists |
| 650 | 0 | 4 | _aRadioligand Assay |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aReceptors, Purinergic P1 _xmetabolism |
| 650 | 0 | 4 |
_aVas Deferens _xmetabolism |
| 650 | 0 | 4 |
_aXanthines _xmetabolism |
| 700 | 1 | _aCheek, D J | |
| 700 | 1 | _aBuxton, I L | |
| 700 | 1 | _aWestfall, D P | |
| 773 | 0 |
_tClinical and experimental pharmacology & physiology _gvol. 24 _gno. 7 _gp. 492-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1440-1681.1997.tb01233.x _zAvailable from publisher's website |
| 999 |
_c9228573 _d9228573 |
||